Clinical trials: Neoadjuvant Treatment
Breast Cancer
Study of Neoadjuvant Chemotherapy of Breast Cancer
The purpose of this study is to evaluate the pathological CR rate in breast and lymph nodes of a novel neoadjuvant regimen for invasive breast carcinoma.
- Trial name
- Neoadjuvant (NCT00830544)
- Testing
- Neoadjuvant chemotherapy, Chemotherapy
- Where
- Puerto Rico
- Volunteers
- 54 people
- Sponsor
- Auxilio Mutuo Cancer Center
Resectable Esophageal Cancer
Neoadjuvant Chemoimmunotherapy or Chemoradiotherapy in ESCC
This study was a single-arm, two-cohort, phase II trial aimed at evaluating the efficacy and safety of FAPI-PET/CT response for guiding the selection of neoadjuvant treatment modes after chemotherapy combined with immunotherapy.
- Trial name
- FAIR (NCT07385664)
- Testing
- Neoadjuvant Chemoimmunotherapy or Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Ji Yongling
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
ctDNA-MRD Monitoring After Neoadjuvant Therapy in Gastric Cancer With pCR or MPR
This prospective observational study will enroll adults with gastric or gastroesophageal junction adenocarcinoma who achieve pathological complete response or major pathological response after neoadjuvant therapy and R0…
- Trial name
- NCT07799649
- Testing
- Tumor-Informed ctDNA-MRD Monitoring, Clinician-Selected Standard-of-Care Postoperative Treatment
- Where
- China
- Volunteers
- 150 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Head and Neck Neoplasms
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
The purpose of this trial is to evaluate the safety and efficacy of TransCon TLR7/8 Agonist, TransCon IL-2 β/γ, and pembrolizumab given prior to curative intent surgery in treatment of participants with newly diagnosed Stage…
- Trial name
- BelieveIT-201 (NCT05980598)
- Testing
- TransCon TLR7/8 Agonist, Pembrolizumab, TransCon IL-2 β/γ
- Where
- 65 sites in United States, Georgia and 6 more
- Volunteers
- 27 people
- Sponsor
- Ascendis Pharma A/S
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cervical Cancers
Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial
This is a prospective, single-arm, Phase II clinical trial designed to evaluate the efficacy and safety of paclitaxel and carboplatin combined with PD-1/PD-L1 immune checkpoint inhibitors in the treatment of locally advanced…
- Trial name
- NCT07003620
- Testing
- Neoadjuvant immunochemotherapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin…
- Trial name
- NCT02619669
- Testing
- TAK-228, Letrozole
- Where
- United States
- Sponsor
- Gary Schwartz
Cervical Cancer, Neoadjuvant Therapy
QL1706 Combined With Cisplatin/Paclitaxel as Neoadjuvant Therapy for Cervical Cancer
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of QL1706 combined with cisplatin and paclitaxel as neoadjuvant therapy in patients with FIGO 2018 stage IB1-IB3 cervical…
- Conditions
- Cervical Cancer, Neoadjuvant Therapy, Immunotherapy
- Trial name
- NCT07617818
- Testing
- QL1706 + Cisplatin/Paclitaxel Neoadjuvant Therapy
- Volunteers
- 50 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Local Advanced Rectal Cancer, PD-1 Inhibitor
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab…
- Conditions
- Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
- Trial name
- NCT07686796
- Testing
- Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Guangdong Provincial People's Hospital
Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations…
- Trial name
- NCT06019468
- Testing
- Envolizumab combined with radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Rectal Cancer
Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy
This trial is to assess the efficacy and feasibility of consolidation chemotherapy after neoadjuvant chemoradiotherapy for locally advanced mid or low rectal cancer.
- Trial name
- NCT02843191
- Testing
- Chemotherapy
- Where
- 14 sites in South Korea
- Volunteers
- 358 people
- Sponsor
- Kyung Hee University Hospital at Gangdong
HER2 + Breast Cancer
A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
This is a study to compare the similarity in Pharmacokinetics (PK) profile of HLX319 vs. EU-Phesgo® in patients with HER2-positive early or locally advanced breast cancer .
- Trial name
- NCT07601620
- Testing
- HLX319, EU-Phesgo®
- Volunteers
- 258 people
- Sponsor
- Shanghai Henlius Biotech
Cervical Cancer
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462397
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College London Hospitals
Lung Cancer
Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.
This is a prospective, single-center, single-arm, phase II study evaluating the efficacy and safety of neoadjuvant aumolertinib in previously untreated patients with AI-diagnosed EGFR-mutant and resectable pulmonary ground-glass…
- Trial name
- NCT05946460
- Testing
- Aumolertinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable)
SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer
In this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be…
- Trial name
- TORCH-STAR (NCT07551479)
- Testing
- short-course radiaotherapy, long-course chemoradiaothearpy, Capecitabine
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Fudan University
Rectal Cancer
A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.
Surgery is the most indicated curative treatment for rectal cancer when disease is diagnosed early, however local recurrence risk increases when the disease is diagnosed at advanced stage.T1-2 tumors have a recurrence rate lower…
- Trial name
- NCT01941979
- Testing
- 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
- Where
- Brazil
- Volunteers
- 309 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Prostate Cancer
Phase 2 Study of Neoadjuvant PEMbrolizumab Before Radical PROstatectomy in High-risk Prostate Cancer Patients
This is a phase 2, open-label, non-randomized, single-arm study in patients with high-risk PCa diagnosed with prostate biopsy and undergoing RP and ePLND.
- Trial name
- PEM-PRO (NCT04565496)
- Testing
- Pembrolizumab
- Where
- 2 sites in Italy
- Sponsor
- IRCCS San Raffaele
Breast Cancer
MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment.
- Trial name
- ISNA-Sein (NCT00462696)
- Testing
- Neoadjuvant chemotherapy
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Institut Bergonié
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Lymph Node Dissection After Neoadjuvant Therapy for Gastric and EGJ Adenocarcinoma
This multicenter retrospective observational cohort study will evaluate approximately 2,000 adults with gastric or esophagogastric junction adenocarcinoma who received at least two cycles of neoadjuvant therapy followed by R0…
- Trial name
- NA-LND-GC (NCT07902596)
- Where
- 8 sites in China
- Volunteers
- 2,000 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Breast Cancer, Breast Cancer Stage II
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- BRINK (NCT07188246)
- Testing
- Radiation, Pembrolizumab (KEYTRUDA®)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.